A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Study sponsor: Ascentage Pharma Group Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-05-31Estimated
Enrollment · participants78Estimated
Source updated2025-11-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.